Publicly-traded company Selecta Biosciences Inc. (NASDAQ:SELB) had a closing price of $1.57 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $10.60, this means that the stock is underpriced by 85.19%. In the past 52 weeks the company’s stock price has moved within the range of $1.28 to $6.33.
This particular stock’s 5-day moving average is 1.51, its 20-day moving average is 1.47 and its 100-day moving average is 1.74. Selecta Biosciences Inc. (SELB) currently has 42.37M shares outstanding, which means that its market capitalization is $66.52M.
The Details: Selecta Biosciences Inc. (SELB) Financial Health
We can also look at Return on Assets, which is a percentage that tells us how good a public company is at using its current assets to generate a profit. Higher percentages mean that the company is better at using its assets. At the moment, Selecta Biosciences Inc. Return on Assets is -110.40%.
What Does Wall Street Say about Company?
When selecting stocks to purchase, many investors want to know what Wall Street analysts are thinking before they pull the trigger. They often look for the average analyst rating. At the moment, the average analyst rating for SELB is Buy. Out of 5 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 0 rated it hold, and 5 rated it a Buy.
Understanding Profitability at Selecta Biosciences Inc. (SELB)
A good method of evaluating a public company’s profitability is by taking a look at its Earnings per Share (EPS) performance. In the most recent financial results released by Selecta Biosciences Inc., for the quarter ending on 09/2019, the company posted EPS of -0.28. The average estimate of Wall Street analysts had projected -0.28.
Wall Street analysts, on average, are forecasting the company’s EPS to be -0.33, compared to -0.71 reported in the same quarter last year.